Results 111 to 120 of about 39,096 (340)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary: This randomized trial was designed to test the effectiveness and safety of rimegepant for the acute treatment of migraine among adults in Japan. Results indicated that rimegepant was more effective than placebo, and the 75 mg dose was observed to be more effective than the 25 mg dose.
Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima   +11 more
wiley   +1 more source

Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting

Pharmaceuticals, 2010
Chemotherapy-induced nausea and vomiting (CINV) is a complex pathophysiological condition and consists of two phases. The conventional CINV neurotransmitter hypothesis suggests that the immediate phase is mainly due to release of serotonin (5-HT) from ...
Nissar A. Darmani
doaj   +1 more source

Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary: This study tested the effectiveness of rimegepant for migraine prevention in Japan. Results showed that rimegepant was more effective than placebo in reducing monthly migraine days, with very few adverse effects. These results support the previous findings from a clinical study conducted in the United States and broaden them to ...
Shigekazu Kitamura, Yasuhiko Matsumori, Toshimasa Yamamoto, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima   +11 more
wiley   +1 more source

Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study

Cancer Management and Research, 2018
Toshinobu Hayashi,1,2 Mototsugu Shimokawa,3 Koichi Matsuo,2 Takanori Miyoshi,4 Yoko Toriyama,4 Chiaki Yokota,5 Jun Taniguchi,6 Kiyonori Hanada,7 Kyouichi Tsumagari,8 Noriko Okubo,9 Yoshimichi Koutake,10 Kohei Sakata,11 Yosei Kawamata,12 Takashi Goto,13 ...
Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, Hanada K, Tsumagari K, Okubo N, Koutake Y, Sakata K, Kawamata Y, Goto T, Tsurusaki Y, Koyabu M   +15 more
doaj  

The incidences of nausea and vomiting after general anesthesia with remimazolam versus sevoflurane: a prospective randomized controlled trial [PDF]

Korean Journal of Anesthesiology
Background Postoperative nausea and vomiting (PONV) refers to nausea and vomiting that occurs within 24-h after surgery or in the post-anesthesia care unit (PACU).
Yeong Min Yoo, Jae Hong Park, Ki Hwa Lee, Ah Hyeon Yi, Tae Kyun Kim   +4 more
doaj   +1 more source

Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children [PDF]

, 1999
To perform a cost-effectiveness analysis (CEA) between a standard antiemetic regimen-chlorpromazine + dexamethasone (CPM-DEX)- and a 5-HT3 receptor antagonist-tropisetron (TROP)--in the control of acute emesis induced by highly ...
Giraldez, J. (J.), Jimenez, M. (Miguel), Sierrasesumaga, L. (Luis), Tejedor, I. (I.)   +3 more
core  

A current perspective on stereotactic body radiation therapy for pancreatic cancer. [PDF]

, 2016
Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option.
Czito, Brian G, Hong, Julian C, Palta, Manisha, Willett, Christopher G   +3 more
core   +2 more sources

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Evaluation of Antiemetic Consistency in Chemotherapy-Induced Nausea and Vomiting Among NHL Patients in Sana’a, Yemen

International Journal of General Medicine
Mohammed Mohammed Battah,1,2 Hadzliana Zainal,1 Doa’a Anwar Ibrahim,2 Nur Hafzan Binti Md Hanafiah,1 Syed Azhar Syed Sulaiman,1 Abdulsalam Halboup1,2 1Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang ...
Battah MM, Zainal H, Ibrahim DA, Hanafiah NHBM, Syed Sulaiman SA, Halboup A   +5 more
doaj  

Phase II study of pregabalin for the prevention of chemotherapy induced nausea and vomiting

O Mundo da Saúde
To evaluate the role of pregabalin in the protection of chemotherapy-induced nausea and vomiting, we performed a phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin could improve the complete control of nausea ...
Carla Santos Rossi Paniquar, Auro del Giglio, Alayne Magalhães Trindade Domingues Yamada, Felipe José Silva Melo Cruz   +3 more
doaj   +1 more source